Filing Details
Arcus Biosciences, Inc. (NYSE:RCUS) filed a Form 8-K with the Securities and Exchange Commission on October 20, 2026, disclosing a material event.
8k filedNYSE:RCUS
Arcus Biosciences, Inc. (RCUS) Reports Material Event to SEC
Arcus Biosciences, Inc. (NYSE:RCUS) filed a Form 8-K with the Securities and Exchange Commission on October 20, 2026, disclosing a material event.
At publication ·
What changed
Arcus Biosciences, Inc. (NYSE:RCUS) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Arcus Biosciences filed a Form 8-K on October 20, 2026, disclosing a material event that shareholders should know about.
- The healthcare company's stock trades at $23.75 with a market capitalization of $2.7 billion.
- Form 8-K filings report significant events such as leadership changes, acquisitions, asset sales, or guidance changes.
Market Context
Arcus Biosciences, Inc.'s stock currently trades at $23.75 with a market capitalization of $2.7B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Arcus Biosciences, Inc.'s stock.
All SEC filings for Arcus Biosciences, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View RCUS Stock Page
Frequently Asked Questions
Where can I read RCUS's SEC filings?
Browse all filings on our RCUS SEC filings page.
What types of SEC filings does Arcus Biosciences, Inc. file?
Public companies like Arcus Biosciences, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.